Sales Ranking Jumps from 37th to 14th in April
Two Consecutive Months of Growth

As the season for spring pollen dispersion arrived earlier than usual, sales of the allergy medication Zyrtec at pharmacies have seen a significant increase.


Geo Young announced on June 1 that the number of pharmacy sales of Zyrtec (Cetirizine Hydrochloride, 10 tablets) in April increased by 69% compared to the previous month.


Image of the allergy treatment product Zyrtec. Geo Young

Image of the allergy treatment product Zyrtec. Geo Young

View original image

According to Care Insight, a pharmaceutical research platform that analyzed 459 pharmacies nationwide, Zyrtec was sold 6,539 times in April, a substantial rise from 3,877 times in March. As a result, its ranking among over-the-counter (OTC) medicines jumped 23 spots, from 37th to 14th place. In March as well, sales had risen by 28.8% from the prior month, with its ranking increasing by 18 places.


Geo Young attributed the increased demand for allergy medications to climate change, which has caused the pollen season to begin earlier. According to the Health Insurance Review and Assessment Service, the number of allergy rhinitis patients in Korea reached approximately 7.4 million in 2024, an increase of more than 50% from about 4.91 million in 2021.


Since 2023, Geo Young has been managing the distribution and marketing of Zyrtec in collaboration with UCB Korea. Through this partnership, the company supplied 2.6 million units in 2023, 2.63 million units in 2024, and 2.78 million units in 2025, surpassing a cumulative total of 8 million units supplied over the past three years.



Geo Young Chairperson Chosunhye stated, "The ability to supply medicines in a timely manner in response to changes in allergy seasons is becoming increasingly important," adding, "We will work to improve patient access to treatment with our stable supply chain and marketing capabilities."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing